Our drug R&D facility based out of Bangalore, India is spread across 17 acres and has a lab space of 1,00,000 sq. ft. and has a legacy of +20 years. This facility has state-of-the-art labs to carry out research and development activities related to small molecules such as peptides, PROTACs, carbohydrates, mPEGs, oligonucleotides, etc.
Our integrated drug R&D center based in Hyderabad, India is spread across 2,60,000 sq. ft. and is capable of handling small and large molecules. The facility has a legacy of +20 years and was audited by FDA in 2017. This facility has state-of-the-art labs to carry out activities related to drug discovery, development and manufacturing.
We have CTO-1, 2 and 3 facilities at our Hyderabad site for manufacturing of APIs and High Potent Active Ingredients (HPAIs).
Our CTO-6 and CTO-SEZ manufacturing facilities based in Visakhapatnam, India are spread across 40,07,520 Sq. ft. and 51,83,640 Sq. ft. respectively. We carry out peptide synthesis and manufacturing of APIs (non-sterile), Intermediates and High Potent Active Ingredients (HPAIs) at these facilities. At Visakhapatnam, we have state-of-the-art US FDA and EU-approved pilot & production manufacturing facility, CTO-6 PU-02 for formulations scale-up where we offer clinical & commercial batches. Our Visakhapatnam facility is inspected and approved by major regulatory agencies.
18 years of experience
Experience gained from 100+ discovery programmes
Track record of delivering 8+ IND candidates
Flexible working models
Quick turnaround time
Capabilities to apply multiple modalities
Seamless integration capabilities with Biology as well as CDMO services
Integrated project management
Expertise in various therapeutic modalities
Aurigene Pharmaceutical Services Limited is a leading contract research, development and manufacturing organization (CDMO) providing end-to-end solutions. With a strong legacy of services in discovery, development and manufacturing we are ideally positioned to serve global pharma and specialty companies worldwide.
SEPTEMBER 04, 2023
Discover the Opportunities: Visit Aurigene Pharmaceutical Services at CPHI BarcelonaThe Contract Research, Development and Manufacturing Organization (CRDMO) industry is a dynamic and rapidly evolving sector emerging as it plays a vital role in providing a wide range of services enabling drug companies to bring their products to market efficiently and effectively...Read More
With more than 200 distinct cancer types recognized and steady increase in cancer incidence rates, the fight with cancer takes a new shape with each emerging decade. First was surgery, followed by radiotherapy and chemotherapy. The fourth one was targeted cancer therapeutics, also known as precision therapies. Precision therapies were established with the discove...Read More
Objective & Challenges: Objective was to identify an optimized anti-bacterial lead molecule with in vivo efficacy in relevant infection models an acceptable safety profile, and a patentable series. Challenge was to develop a more efficacious compound than the reference standard.Study design: Compounds were designed and synth...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...Read More
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.